UiPath launches a pro bono automation project with the Mater Hospital to free up nurses dealing with infection control including Covid-19
Today UiPath is launching a pro bono automation project with the Mater Misericordiae University Hospital. The initiative will see software robots assigned to the Infection Prevention and Control (IPC) Department at the Mater. This development will significantly reduce the administrative strain placed upon the department by multidrug resistant organisms or viruses such as Covid-19, enabling IPC nurses to spend more time with patients. The project will see the Mater offered free trial robot licenses for the IPC Department until the end of the year.
With data being automated through software robots, the information will be processed in a fraction of the current time, disseminating patient results in minutes. It will save the infection control department 3 hours per day, 18 hours per week and 936 hours a year which they can now spend managing the current Covid-19 pandemic.
As a result of Covid-19, the Mater expects to receive hundreds of swabs and microbiology tests in the coming months which the software robots can assist in rapid processing. The results can then be distributed to healthcare workers rapidly and essential infection prevention and control measures can be put into action.
Jincy Jerry, Assistant Director of Nursing, Infection Prevention and Control, MMUH, said: “Given that IPC nurses spend close to 30% of their day with administrative tasks, for the past few months I have been looking at ways to make software robots part of our daily jobs. With the COVID-19 pandemic unfolding now, it is crucial that all frontline staff are freed up as much as possible to spend time with patients and deal with this outbreak, rather than being in front of computers.”
“Not only will automation help with this, but it will also take the strain off the hospital as it continues to process huge amounts of more routine patient data in addition to Covid-19 specific information.”
“As we’ve already seen, alongside the public playing their part in physical distancing, fast diagnosis and appropriate self-isolation are crucial to preventing the spread of COVID-19. We’re confident that the project we’re embarking on will help mitigate the huge strain this outbreak is putting on healthcare organisations – not just in MMUH, but across Ireland.”
Mark O’Connor, Public Sector Director Ireland at UiPath, said: “Infection Prevention & Control is critical to help people stay healthy, and while COVID-19 is top of mind, this project will continue to deliver benefits long term. At this time of heightened stress and anxiety, it’s vital to free up doctors and nurses’ time for patients wherever it can be done.”
“Robotic process automation minimises, if not removes, the need for people to carry out repetitive, rules-based admin work – speeding up processes and ensuring they’re error-free. With a robot for every nurse approach, essential frontline staff will be freed to be nurses and not system administrators, being able to focus more on the quality of care – which can make a real difference when it comes to treating patients in times of need.”
O’Connor will be hosting a webinar on April 2, 2020 at 10 a.m. EST/3 p.m. BST to discuss Mater’s use of automation to respond to Covid-19-related scenarios. To register, visit this link.
For more information on UiPath, go to uipath.com.
About UiPath
UiPath is leading the era of “Automation First” by betting on a robot for each person and allowing robots to learn new skills through artificial intelligence (AI) and machine learning (ML). Through free and open training, UiPath brings digital era skills to millions of people around the world, improving business productivity and efficiency, employee engagement, and customer experience.
The company’s hyper-automation platform combines the number one Robotic Process Automation (RPA) solution with a full suite of capabilities, including process mining and analytics, that enable every organization to scale digital business operations at unprecedented speed. The company has already automated millions of repetitive, mind-numbing tasks for businesses and government organizations all over the world, including more than 50% of the Fortune 500 and 8 of the Fortune 10.
UiPath has recently been recognised as the top company in The Deloitte Technology Fast 500 for 2019, a ranking of the fastest growing public and private technology companies in North America, and number 3 in the 2019 Forbes Cloud 100.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200326005081/en/
Contact information
Toni Iafrate
UiPath
toni.iafrate@uipath.com
978-239-5499
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Transition Industries Signs Strategic Agreements for the Pacifico Mexinol Project, the Largest Standalone Ultra-Low Carbon Chemical Production Facility in the World30.6.2025 21:30:00 EEST | Press release
Transition Industries LLC, a developer of world-scale, net-zero carbon emissions methanol and green hydrogen projects in North America, held a signing event for an Engineering, Procurement, and Construction (EPC) contract with the consortium of Samsung E&A Co., Ltd. (Samsung E&A), Grupo Samsung E&A Mexico, S.A. de C.V., and Techint Engineering and Construction for the Pacifico Mexinol project located in Ahome, Sinaloa, Mexico, which is contingent upon the fulfillment of customary conditions precedent and obtainment of all required approvals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250630940954/en/ MAIRE group’s technology division NextChem, through its subsidiary KT TECH SpA, also signed a Basic Engineering, Critical and Proprietary Equipment Supply Agreement with Samsung E&A in connection with its proprietary NX AdWinMethanol®Zero technology supply to the project. Transition Industries is jointly developing the Pacif
Westinghouse and ITER Sign a $180M Contract to Advance Nuclear Fusion30.6.2025 16:45:00 EEST | Press release
Westinghouse Electric Company and ITER signed a contract for $180 million for the assembly of the vacuum vessel for the fusion reactor. This is a key milestone in the construction of the ITER reactor, leading the way toward the use of fusion as a practical future source of reliable carbon-free energy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250630497810/en/ The ITER Tokamak pit with the two vacuum vessel sector modules installed. Westinghouse has participated in the fabrication of the sectors of the vacuum vessel, as part of the Fusion for Energy (F4E) Consortium with its partners Ansaldo Nucleare and Walter Tosto. Westinghouse will be responsible for completing the vacuum vessel which is ITER’s most critical component: a hermetically sealed, double-walled steel container that will house the fusion plasma. When all the vacuum vessel sectors are in place, Westinghouse will start the most intensive stage of ITER assembl
Monetate Acquires SiteSpect to Deliver AI-Native Personalization and Testing at Enterprise Scale30.6.2025 16:00:00 EEST | Press release
Monetate, the leading AI-driven personalization platform, today announced it has acquired SiteSpect, a leader in A/B testing, to drive next-generation digital experience optimization. This acquisition accelerates Monetate’s vision to deliver intelligent, intentional, and individualized experiences at scale, powered by agentic AI and backed by the industry’s most advanced, enterprise-grade infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250630514541/en/ The combination of Monetate’s real-time personalization and SiteSpect’s zero-flicker testing will yield an industry-first solution for enterprise-grade personalization, testing, and optimization. For the first time, global ecommerce and digital experience leaders can access unified client-side and server-side experimentation with full personalization capabilities in a single solution, designed for scalability and regulatory compliance. Monetate is now the only e
SS&C Blue Prism Recognized as a Gartner® Magic Quadrant™ RPA Leader for the Seventh Consecutive Year30.6.2025 16:00:00 EEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that SS&C Blue Prism has been recognized as a Leader in the 2025 Gartner Magic Quadrant for Robotic Process Automation (RPA). “We’re delighted SS&C Blue Prism has been named a Leader in the Gartner Magic Quadrant for Robotic Process Automation for the seventh year running,” said Bill Stone, CEO and Chairman of SS&C Technologies. “SS&C Blue Prism combines market-leading RPA and orchestration technologies with the latest artificial intelligence so organizations can tackle more complex tasks and dynamic business processes. We’ve scaled to more than 2,700 digital workers and AI agents across our own operations, resulting in over $200 million in annual savings. With SS&C leading the charge on deployment, customers can be confident in rolling out SS&C’s automation solutions securely, effectively, and responsibly.” More than 2,800 companies worldwide leverage SS&C Blue Prism for AI-powered automation, helping organizations delive
Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content 130.6.2025 15:00:00 EEST | Press release
Takeda(TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with less than or equal to 2 µg/mL IgA in a 10% solution, the only ready-to-use liquid immunoglobulin (IG) therapy with low immunoglobulin A (IgA) content, as replacement therapy for people two years of age and older with primary immunodeficiency (PI). As a ready-to-use liquid, GAMMAGARD LIQUID ERC may help ease the administration burden for patients and their health care providers by eliminating the need for reconstitution and can be administered intravenously or subcutaneously.1 “The approval of GAMMAGARD LIQUID ERC reinforces our commitment to supporting individualized treatment approaches for people with primary immunodeficiency, including a therapeutic option that has the lowest IgA content of any ready-to-use liquid immunoglobulin therapy, and can be administered intravenously or subcutaneously,” said Kristina Allikmets, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom